Kidney Cancer Drugs Market is Witnessing Rapid Growth with Pfizer and Merck KGaA Receiving the U.S. FDA Approval for immunotherapy Bavencio (avelumab) with Inlyta (axitinib) for advanced renal cell carcinoma (RCC)

 

Kidney Cancer Drugs Market

Kidney cancer is cancer that arises within the kidneys. Renal cell malignant neoplastic disease (RCC), additionally referred to as excretory organ cell cancer or excretory organ cell glandular carcinoma, is that the commonest sort of urinary organ cancer concerning nine out of ten urinary organ cancers are excretory organ cell carcinomas.

Growing prevalence of kidney cancer or renal cancer is expected to drive growth of the global kidney cancer drugs market. According to the American Cancer Society, around 76,080 new cases of kidney cancer, which is 48,780 in men and 27,300 in women, are estimated to be diagnosed in 2021 in the U.S. Furthermore, around 13,780, which is 8,790 men and 4,990 women, are estimated to die from this disease in 2021. According to the World Cancer Research Fund, Belarus had the highest rate of kidney cancer in 2018, followed by Latvia. Such a high incidence of kidney cancer has increased the demand for relevant medications and treatment options. Some drugs such as Everolimus (Afinitor) are used to treat advanced kidney cancers along with lenvatinib when other drugs such as sunitinib and sorafenib have been tried. Thus, such factors are expected to drive growth of the global kidney cancer drugs market. Furthermore, the large availability of novel drugs and the presence of a strong pipeline is expected to propel the global kidney cancer drugs market growth in the near future.

However, the high cost of drugs and uncertain reimbursement policies is expected to restrain growth of the global kidney cancer drugs market. Furthermore, continuous research and development activities can present lucrative growth opportunities in the global kidney cancer drugs market. Among regions, North America is expected to witness significant growth in the global kidney cancer drugs market. This is owing to the presence of key manufacturers such as Pfizer and Novartis and increased adoption of therapeutics in the region. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to proactive government support targeting biotechnology in emerging economies such as China and Japan.

Key companies involved in the global kidney cancer drugs market are Bayer, Pfizer, Novartis, Eisai, Exelixis, Bristol-Myers Squibb, Genentech (Roche), and  Prometheus Labs.

For instance, in May 2019, Pfizer and Merck KGaA received the U.S. Food and Drug Administration (FDA) approval for their immunotherapy Bavencio (avelumab) with Inlyta (axitinib) for advanced renal cell carcinoma (RCC).

Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region